307

Osenga

A Phase I Clinical Trial of Hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: A Study of the Children's Oncology Group

308

Cheung

Validation of Cyclin D1, a Gene Identified by Genome-Wide Expression Arrays, as a Marker of Minimal Residual Disease in Neuroblastoma

309

Sano

Neuroblastoma with Discordant Genotype-Phenotype Relationship of MYCN Amplification and Favorable Histology: A Childrens Oncology Group Study

310

Schmidt

Parental Report of Late Effects among Long-Term Survivors of Neuroblastoma

311

Messina

Evaluation of Semi-Quantitative Scoring System for Metaiodobenzylguanidine (mIBG) Scans in Patients with Relapsed Neuroblastoma

312

Maris

Phase 1 Trial of the Orally Bioavailable Trk Tyrosine Kinase Inhibitor CEP-701 in Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Study